PRF1 and neoplasm: In a bid to identify true non-responders, SC2 was further subdivided based on two phenotypes: T-cell reinvigoration (assessed by IFNg release) and tumor cytotoxicity (assessed by tumor content decrease, cleaved Caspase-3 increase, GranzymeB and Perforin release).